Medicamen Biotech Ltd Stock Price Today (NSE: MEDICAMEQ)
Fundamental Score
Medicamen Biotech Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Medicamen Biotech Ltd share price today is ₹272.70, up +0.96% on NSE/BSE as of 19 June 2026. Medicamen Biotech Ltd (MEDICAMEQ) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹545.08 (Cr). The 52-week high for MEDICAMEQ share price is ₹447.65 and the 52-week low is ₹216.95. At a P/E ratio of 50.99x, MEDICAMEQ is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 3.39% and a debt-to-equity ratio of 0.14.
Medicamen Biotech Ltd Share Price Chart — NSE/BSE Historical Performance
Medicamen Biotech Ltd share price chart: 12.81% return over the past month. 52-week high ₹447.65, 52-week low ₹216.95.
Medicamen Biotech Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹270.00 | ₹280.90 | ₹267.00 | ₹272.70 | 15.70K (Cr) | |
| ₹262.25 | ₹276.30 | ₹262.25 | ₹270.10 | 31.04K (Cr) | |
| ₹286.25 | ₹299.40 | ₹269.00 | ₹271.55 | 80.95K (Cr) | |
| ₹284.60 | ₹284.60 | ₹284.60 | ₹284.60 | 0.00 (Cr) | |
| ₹270.50 | ₹300.80 | ₹257.60 | ₹284.60 | 69.59K (Cr) | |
| ₹272.95 | ₹278.95 | ₹268.35 | ₹272.30 | 5.69K (Cr) | |
| ₹269.55 | ₹277.50 | ₹265.40 | ₹270.65 | 11.75K (Cr) | |
| ₹265.00 | ₹273.40 | ₹264.15 | ₹269.55 | 7.16K (Cr) | |
| ₹277.00 | ₹281.60 | ₹264.15 | ₹266.85 | 13.29K (Cr) | |
| ₹274.70 | ₹278.70 | ₹266.10 | ₹274.45 | 13.34K (Cr) |
Medicamen Biotech Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹262.25 | ₹280.90 | ₹262.25 | ₹272.70 | +3.98% | |
| ₹258.65 | ₹300.80 | ₹253.55 | ₹271.55 | +4.99% | |
| ₹249.90 | ₹273.00 | ₹222.20 | ₹254.53 | +1.85% | |
| ₹289.00 | ₹309.75 | ₹216.95 | ₹223.30 | -22.73% | |
| ₹353.70 | ₹377.00 | ₹288.15 | ₹301.20 | -14.84% | |
| ₹368.35 | ₹406.60 | ₹340.10 | ₹342.10 | -7.13% | |
| ₹415.50 | ₹424.10 | ₹356.60 | ₹364.65 | -12.24% | |
| ₹377.50 | ₹447.65 | ₹374.20 | ₹411.60 | +9.03% | |
| ₹296.55 | ₹377.90 | ₹294.70 | ₹376.35 | +26.91% | |
| ₹349.00 | ₹363.50 | ₹292.95 | ₹295.35 | -15.37% | |
| ₹389.00 | ₹391.00 | ₹341.70 | ₹345.25 | -11.25% | |
| ₹416.50 | ₹420.00 | ₹377.05 | ₹389.55 | -6.47% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Medicamen Biotech Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Medicamen Biotech Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of MEDICAMEQ across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Robust Profit Growth (82.88%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Conservative Debt Levels (D/E: 0.14)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
7 factors identified
Below-Average Return on Equity (3.39%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (5.61%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 50.99x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Weak Earnings Growth (-12.51% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-11.81% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Negative Free Cash Flow (₹-45.97 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 0.64%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Medicamen Biotech Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Medicamen Biotech Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Medicamen Biotech LtdMedicamen Biote...Selected✓ MEDICAMEQ • 531146 | 31.4/100 | ₹272.70₹273 | ₹545.08₹545.08 | 50.99Average 51.0 Average | 3.39%Poor 3.39% Poor | 5.61%Poor 5.61% Poor | 0.14Excellent 0.1 Excellent | -11.81%Poor -11.81% Poor | 5.31%Good 5.31% Good | 0.25% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Medicamen Biotech Ltd PE Ratio History
Historical price-to-earnings ratio for MEDICAMEQ — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹5.16 | ₹364.65 | 70.7x |
| FY 2024 | ₹7.50 | ₹512.45 | 68.3x |
| FY 2023 | ₹11.73 | ₹603.15 | 51.4x |
| FY 2022 | ₹12.19 | ₹830.50 | 68.1x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Medicamen Biotech Ltd Dividend History
Annual cash dividends paid by MEDICAMEQ — dividend yield 0.25%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹1.27 Cr |
| FY 2024 | ₹1.27 Cr |
| FY 2023 | ₹1.27 Cr |
| FY 2022 | ₹1.22 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Medicamen Biotech Ltd Quarterly Performance
Latest quarterly metrics for MEDICAMEQ — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
5.43%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
82.88%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
5.31%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-11.81%
Compounded annual net profit growth over 5 years
Medicamen Biotech Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for MEDICAMEQ — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Medicamen Biotech Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Medicamen Biotech Ltd (MEDICAMEQ) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Medicamen Biotech Ltd
About MEDICAMEQ (Medicamen Biotech Ltd)
Medicamen Biotech Ltd is a burgeoning force within the pharmaceutical landscape, operating with a multifaceted approach that encompasses the entire drug lifecycle, from initial res...earch and rigorous development to advanced manufacturing, strategic marketing, and comprehensive global distribution. The company's commitment to innovation is evident in its relentless pursuit of novel formulations and improved delivery systems, positioning it as a key player in meeting the ever-evolving healthcare needs of both domestic and international markets. Their dedication to quality and adherence to stringent regulatory standards underpin every stage of their operations, ensuring the safety and efficacy of their pharmaceutical products. Medicamen Biotech's diverse portfolio caters to a broad spectrum of therapeutic areas, reflecting its comprehensive approach to healthcare solutions. From combating life-threatening diseases like cancer and cardiovascular ailments to managing chronic conditions such as diabetes, the company offers a range of essential medications. Its commitment extends to addressing prevalent health concerns through anti-infectives, anti-malarials, and pain management therapies, alongside vital supplements and vitamins. This expansive array of pharmaceutical formulations underscores Medicamen Biotech's dedication to improving the health and well-being of communities worldwide, demonstrating a clear commitment to serving a wide range of medical needs. The company's success is built on a foundation of robust infrastructure, a skilled workforce, and a relentless focus on customer satisfaction. Leveraging cutting-edge technologies and state-of-the-art manufacturing facilities, Medicamen Biotech strives to optimize production efficiency and maintain consistent product quality. Through strategic partnerships and a well-established distribution network, the company ensures its pharmaceutical products reach patients in need, regardless of geographical location. Medicamen Biotech's unwavering commitment to excellence, innovation, and ethical business practices positions it for continued growth and success in the dynamic pharmaceutical industry.
Company Details
Key Leadership
Corporate Events
MEDICAMEQ Share Price: Frequently Asked Questions
What is the current share price of Medicamen Biotech Ltd?
Medicamen Biotech Ltd (MEDICAMEQ) trades at ₹272.70 on NSE and BSE. Market cap ₹545.08 (Cr). Educational data only.
What is the P/E ratio of Medicamen Biotech Ltd?
Medicamen Biotech Ltd has a P/E of 50.99x vs industry average 31.77x.
What is the Bull Run score for Medicamen Biotech Ltd?
Medicamen Biotech Ltd has a Bull Run score of 31.4/100 based on 25+ financial parameters.
Does Medicamen Biotech Ltd pay dividends?
Medicamen Biotech Ltd has a dividend yield of 0.25%. Past dividends don't guarantee future payments.
What is the ROE of Medicamen Biotech Ltd?
Medicamen Biotech Ltd has ROE of 3.39%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Medicamen Biotech Ltd?
Medicamen Biotech Ltd has debt-to-equity of 0.14.
Is Medicamen Biotech Ltd a good investment?
Bull Run gives Medicamen Biotech Ltd a score of 31.4/100. This is not investment advice — consult a SEBI-registered advisor.